SCHEMBL4496876

SCHEMBL4496876

CN(C)CCCc1cccc(N/C(=C2\C(=O)Nc3cc(Cl)ccc32)c2cccc(CC(=O)O)c2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PLK1 P53350 8/20 0.48
PLK3 Q9H4B4 6/20 0.44
PDGFRB P09619 5/20 0.44
KIT P10721 5/20 0.44
FGFR1 P11362 5/20 0.44
KDR P35968 5/20 0.44
FLT3 P36888 5/20 0.44
NR1H4 Q96RI1 2/20 0.36
HPSE Q9Y251 1/20 0.35
PPARG P37231 1/20 0.35
PPARD Q03181 1/20 0.35
PPARA Q07869 1/20 0.35
RXFP1 Q9HBX9 1/20 0.34
HSPH1 Q92598 1/20 0.34
ALDH1A1 P00352 2/20 0.34
KMT2A Q03164 2/20 0.34
MEN1 O00255 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
HTT P42858 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4496879 1.00 PLK1 (0.48) PLK1PLK3PDGFRBKITFGFR1
SCHEMBL4498955 0.95 PLK1 (0.42) PLK1PLK3PDGFRBKITFGFR1
SCHEMBL4498958 0.95 PLK1 (0.42) PLK1PLK3PDGFRBKITFGFR1
SCHEMBL4499140 0.94 PLK1 (0.48) PLK1PLK3PDGFRBKITFGFR1
SCHEMBL4490675 0.94 PLK1 (0.42) PLK1PLK3PDGFRBKITFGFR1
SCHEMBL4490680 0.94 PLK1 (0.42) PLK1PLK3PDGFRBKITFGFR1
SCHEMBL4499144 0.94 PLK1 (0.48) PLK1PLK3PDGFRBKITFGFR1
SCHEMBL225609 0.94 PLK1 (0.49) PLK1PLK3PDGFRBKITFGFR1
SCHEMBL225610 0.94 PLK1 (0.49) PLK1PLK3PDGFRBKITFGFR1
SCHEMBL4493722 0.90 PLK1 (0.38) PLK1PLK3PDGFRBKITFGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7514468-B2 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2009-04-07 US disclosed
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2006-08-31 US disclosed
EP-1527046-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2005-05-04 EP disclosed
WO-2004009546-A1 INDOLINE DERIVATIVES SUBSTITUTED IN POSITION 6, PRODUCTION AND USE THEREOF AS MEDICAMENTS BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2004-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194813-A1 Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions KDR, FLT1, EGFR PLK1 86/4885PLK3 133/4885PDGFRB 105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.